GJE04.FD1

## I claim:

1. A humanized monoclonal antibody, or antigen-binding fragment thereof, comprising regions of antibodies from different animal species, wherein a hypervariable region of the variable region of said humanized antibody comprises a hypervariable region from a high-affinity non-rodent, non-human monoclonal antibody, wherein said high-affinity non-rodent, non-human monoclonal antibody has an antigen binding affinity of at least about 10<sup>11</sup> l/mol, and wherein a variable framework region of said variable region of said humanized monoclonal antibody comprises a human immunoglobulin variable framework region and wherein a constant region of said humanized monoclonal antibody comprises a human immunoglobulin constant region.

14

- 2. The antigen-binding fragment according to claim 1, wherein said antigen-binding fragment is selected from the group consisting of an  $F(ab')_2$ , Fab and Fv fragment.
- 3. The humanized monoclonal antibody according to claim 1, wherein said high-affinity non-rodent, non-human monoclonal antibody is an ovine antibody.
- 4. The humanized monoclonal antibody according to claim 1, wherein said humanized monoclonal antibody has an antigen binding affinity of at least about 10<sup>12</sup> l/mol.
- 5. The humanized monoclonal antibody according to claim 1, wherein said humanized monoclonal antibody has an antigen binding affinity of at least about 5 x  $10^{12}$  l/mol.
- 6. The humanized monoclonal antibody according to claim 1, wherein said humanized monoclonal antibody has an antigen binding affinity of at least about  $10^{13}$  l/mol.
- 7. The humanized monoclonal antibody according to claim 1, wherein said antigen binding affinity of said humanized monoclonal antibody is less than about 10<sup>14</sup> l/mol.

8. The humanized monoclonal antibody according to claim 7, wherein said high-affinity non-rodent, non-human monoclonal antibody is an ovine antibody.

. .

- 9. A chimeric monoclonal antibody, or antigen binding fragment thereof, comprising regions of antibodies from different animal species, wherein the variable region of said chimeric monoclonal antibody comprises variable region from a high-affinity non-rodent, non-human monoclonal antibody, wherein said high-affinity non-rodent, non-human monoclonal antibody has an antigen binding affinity of at least about 10<sup>11</sup> l/mol, and wherein a constant region of said chimeric monoclonal antibody comprises a human immunoglobulin constant region.
- 10. The antigen-binding fragment according to claim 9, wherein said antigen-binding fragment is selected from the group consisting of an F(ab')<sub>2</sub>, Fab and Fv fragment.
- 11. The chimeric monoclonal antibody according to claim 9, wherein said high-affinity non-rodent, non-human monoclonal antibody is an ovine antibody.
- 12. The chimeric monoclonal antibody according to claim 9, wherein said chimeric monoclonal antibody has an antigen binding affinity of at least about 10<sup>12</sup> l/mol.
- 13. The chimeric monoclonal antibody according to claim 9, wherein said chimeric monoclonal antibody has an antigen binding affinity of at least about  $5 \times 10^{12}$  l/mol.
- 14. The chimeric monoclonal antibody according to claim 9, wherein said chimeric monoclonal antibody has an antigen binding affinity of at least about 10<sup>13</sup> 1/mol.
- 15. The chimeric monoclonal antibody according to claim 9, wherein said antigen binding affinity of said humanized monoclonal antibody is less than about 10<sup>14</sup> l/mol.

16 GJE04.FD1

16. The chimeric monoclonal antibody according to claim 15, wherein said high-affinity non-rodent, non-human monoclonal antibody is an ovine antibody.